Furthermore, the study by O’Neill et al. (2019) showed that long-term intravitreal anti-VEGF agents would not appear to increase the risk of developing or worsening proteinuria in patients with and without diabetic kidney disease. The gene discussed is VEGFA; the disease is diabetic kidney disease.